# US 2021/0332384 A1 · Oncolytic Vaccinia Virus With Modified B5R Gene For The Treatment Of Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332384 A1
- Document ID: US20210332384A1
- Status: Published application
- Kind: A1
- Application number: 17/284,169
- Filed: 2019-10-10
- Published: 2021-10-28
- Earliest claimed: 2018-10-10
- Assignees: Queen Mary University of London
- Applicants: Queen Mary University of London
- Inventors: Yaohe Wang; Ming Yuan
- Web page: https://patentgrep.com/patent/US20210332384A1

## CPC

- A61K 39/285: Vaccinia virus or variola virus
- C12N 15/86: Viral vectors
- A61K 35/768: Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
- A61K 38/20: Interleukins [IL]
- A61K 38/208: {IL-12}
- A61P 35/00: Antineoplastic agents
- C07K 14/5434: {IL-12}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70532: {B7 molecules, e.g. CD80, CD86}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5256: {expressing foreign proteins}
- C12N 2710/24134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/24143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to a vaccinia virus vector comprising a nucleic acid sequence encoding a SCR1-, SCR2-, SCR3-, and SCR4-domain deleted B5R gene (B5R SCR1− SCR2−SCR3− SCR4−) inserted into the TK gene of the vaccinia virus. The invention also relates to compositions comprising the vaccinia virus vector, methods of treatment using the compositions, medical uses of the compositions and kits comprising the vaccinia virus vector. The invention also relates to a nucleic acid sequence encoding a SCR1-, SCR2-, SCR3-, and SCR4-domain deleted B5R gene (B5R SCR1− SCR2− SCR3− SCR4−) of vaccinia virus.

## Claims

### Claim 1

A vaccinia virus vector comprising a nucleic acid sequence encoding a SCR1-, SCR2-, SCR3-, and SCR4-domain deleted B5R gene (B5R SCR1− SCR2− SCR3− SCR4−) inserted into the TK gene of the vaccinia virus.

### Claim 2 (depends on 1)

A vaccinia virus vector according to claim 1, wherein the native B5R gene remains intact.

### Claim 3 (depends on 1)

A vaccinia virus vector according to claim 1 which further comprises a nucleic acid sequence encoding a biologically active protein inserted into the N1L gene of the vaccinia virus.

### Claim 4 (depends on 3)

A vaccinia virus vector according to claim 3, in which the biologically active protein is selected from the group consisting of cytokines, antibodies, antibody fragments, cytokine receptors and cytokine receptor fragments.

### Claim 5 (depends on 4)

A vaccinia virus vector according to claim 4, in which the biologically active protein is a cytokine.

### Claim 6 (depends on 5)

A vaccinia virus vector according to claim 5, in which the cytokine is selected from the group consisting of IL-21, GM-CSF, IL-2, IL-7, IL-12, IL-15, IL-18 and IFN-α, or any combinations thereof.

### Claim 7 (depends on 1, 3, 4, 5)

A vaccinia virus vector according to claim 1 and any one of claims 3 to 5, in which the nucleic acid sequence encoding a SCR1-, SCR2-, SCR3-, and SCR4-domain deleted B5R gene (B5R SCR1− SCR2− SCR3− SCR4−) is defined in FIG. 31.

### Claim 8 (depends on 4)

A vaccinia virus vector according to claim 4, in which the biologically active protein is an immune checkpoint inhibitor molecule.

### Claim 9 (depends on 8)

A vaccinia virus vector according to claim 8, in which the immune checkpoint inhibitor molecule is selected from the group consisting of soluble PD1, soluble PD-L1, soluble TIM-3, soluble CTLA-4, or any combinations thereof.

### Claim 10 (depends on 8, 9)

A vaccinia virus vector according to any one of claim 8 or claim 9, in which the nucleic acid sequence encoding a SCR1-, SCR2-, SCR3-, and SCR4-domain deleted B5R gene (B5R SCR1− SCR2− SCR3− SCR4−) is defined in FIG. 31.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7)

A composition comprising a vaccinia virus vector according to any one of claims 1 to 7.

### Claim 12 (depends on 8, 9, 10)

A composition comprising a vaccinia virus vector according to any one of claims 8 to 10.

### Claim 13 (depends on 11)

A method of treatment comprising administering a composition according to claim 11 to a subject in need thereof for the treatment of cancer.

### Claim 14 (depends on 12)

A method of treatment comprising administering the composition according to claim 12 to a subject in need thereof for the treatment of cancer.

### Claim 15 (depends on 11, 12)

A method of treatment comprising administering the composition according to claim 12 and the composition according to claim 11 separately, subsequently or simultaneously.

### Claim 16 (depends on 11)

A composition comprising a vaccinia virus vector according to claim 11 for use in the treatment of cancer.

### Claim 17 (depends on 12)

A composition comprising a vaccinia virus vector according to claim 12 for use in the treatment of cancer.

### Claim 18 (depends on 11, 12)

A composition comprising a vaccinia virus vector according to claim 12 and a composition comprising a vaccinia virus vector according to claim 11 for separate, subsequent or simultaneous use in the treatment of cancer.

### Claim 19

A nucleic acid sequence encoding a SCR1-, SCR2-, SCR3-, and SCR4-domain deleted B5R gene (B5R SCR1− SCR2− SCR3− SCR4−) of vaccinia virus.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6)

A kit comprising a vaccinia virus vector according to any one of claims 1 to 6 and a pharmaceutically acceptable adjuvant, diluent and/or buffer.

### Claim 21 (depends on 8, 9)

A kit comprising a vaccinia virus vector according to any one of claims 8 to 9 and a pharmaceutically acceptable adjuvant, diluent and/or buffer.
